DREAMM-7: Belamaf+BVd vs DVd in RRMM, analyses of phase 3 trial comparing regimens after relapse скачать в хорошем качестве

DREAMM-7: Belamaf+BVd vs DVd in RRMM, analyses of phase 3 trial comparing regimens after relapse

In patients with relapsed/refractory multiple myeloma (RRMM) and poor prognostic features, there is a significant unmet need for effective treatments. The DREAMM-7 trial (NCT04246047) evaluated the efficacy of belantamab mafodotin (BVd) versus standard-of-care daratumumab plus bortezomib and dexamethasone (DVd) in RRMM patients with at least one prior line of treatment. The study demonstrated a statistically significant and clinically meaningful progression-free survival (PFS) benefit with BVd compared to DVd. Further analyses from DREAMM-7 explored efficacy in key subgroups, including patients refractory to lenalidomide and those with high-risk cytogenetics. BVd showed superior PFS and overall response rates (ORR) compared to DVd in these subgroups. Ocular adverse events were more frequent with BVd, but overall, the safety profile was manageable. The results support BVd as a potential new standard of care in RRMM patients with high unmet needs. Key Points: • DREAMM-7 trial compared belantamab mafodotin (BVd) with standard-of-care daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM) patients. • BVd demonstrated a significant progression-free survival (PFS) benefit compared to DVd, with a median PFS improvement of 23 months. • Subgroup analyses showed superior efficacy of BVd over DVd in patients refractory to lenalidomide and those with high-risk cytogenetics. • Ocular adverse events were more common with BVd, but overall safety was manageable. • These results suggest BVd as a potential new standard of care in RRMM patients with unmet needs. Authors: Maria-Victoria Mateos, Pawel Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Ward, P. Joy Ho, Ana Carolina de Almeida, Roman Hajek, Kihyun Kim, Meletios Athanasios Dimopoulos, Claudio Cerchione, Nicholas Pirooz, Astrid McKeown, Gbenga Kazeem, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Joanna Opalinska, Vania Hungria Clinical Trial Registration Number NCT04246047 ASCO Abstrcat: 7503 DOI: 10.1200/JCO.2024.42.16_suppl.7503 _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52... Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.